

OVID THERAPEUTICS INC.
1460 Broadway, Suite 15044
New York, NY 10036

November 18, 2020

Via EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attn: Ada Sarmiento

Re: **Ovid Therapeutics Inc.**
Registration Statement on Form S-3 (File No. 333-250054)
Request for Acceleration of Effective Date

Ms. Sarmiento:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “**Registrant**”) hereby requests that the Securities and Exchange Commission (the “**Commission**”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-250054) (the “**Registration Statement**”) to become effective on November 20, 2020, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable (the “**Staff**”).

Once the Registration Statement has been declared effective, please orally confirm that event with Jaime Chase of Cooley LLP, counsel to the Registrant, at (202) 728-7096, or in her absence, Owen Williams at (202) 842-7843.

[Signature page follows]

Very truly yours,

Ovid Therapeutics Inc.

By: /s/ Thomas M. Perone

Thomas M. Perone

General Counsel and Chief Compliance Officer

cc:

Jeremy Levin, Ovid Therapeutics Inc.

Timothy Daly, Ovid Therapeutics Inc.

Jeffery Rona, Ovid Therapeutics Inc.

Laura Berezin, Cooley LLP

Jaime Chase, Cooley LLP

Owen Williams, Cooley LLP